within Pharmacolibrary.Drugs.ATC.A;

model A10BH06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.2833333333333333,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.101,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013833333333333333,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in people with type 2 diabetes mellitus. It is an orally administered antidiabetic agent. It has been approved for clinical use in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>Noh, YH, et al., &amp; Bae, KS (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. <i>Clinical therapeutics</i> 34(5) 1182–1194. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2012.04.001&quot;>10.1016/j.clinthera.2012.04.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22534255/&quot;>https://pubmed.ncbi.nlm.nih.gov/22534255</a></p></li><li><p>Choi, HY, et al., &amp; Bae, KS (2014). Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 52(5) 381–391. DOI:<a href=&quot;https://doi.org/10.5414/CP202038&quot;>10.5414/CP202038</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24495314/&quot;>https://pubmed.ncbi.nlm.nih.gov/24495314</a></p></li><li><p>Kim, Y, et al., &amp; Yoo, HH (2014). Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 44(7) 627–634. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2013.873156&quot;>10.3109/00498254.2013.873156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24738939/&quot;>https://pubmed.ncbi.nlm.nih.gov/24738939</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BH06;
